UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Learn the scenarios where index funds outperform target date funds, with emphasis on fees, control, and asset allocation flexibility.
26,348 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
United Airlines faces near term pressure from higher fuel costs, yet the Street remains optimistic with a consensus t...
KeyBanc lowers its price target for On Holding AG to $43, citing tariff exposure that weighs on margins, even as the ...
ConocoPhillips faces a clash between a wave of Buy ratings and a cautious price target, as crude markets rebound and ...
As the auto industry pivots toward electric and software-enabled services, the path for Ford stock over the next deca...
When a high-ranking insider sells stock, investors want to know what it means. This guide breaks down the implication...
Biogen’s $1 billion move on a mystery company has investors buzzing. This article breaks down why the deal could be a...
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Investors often wonder if Nvidia stock should be bought before major AI events. This article breaks down historical p...
Fastly stock already doubled this year, leaving many investors wondering if the rally can continue. This guide breaks...
When a top executive sells stock, the market takes notice. This deeper look at Bristow Group's just sold helps you se...
The Supreme Court's tariff ruling reshapes costs, consumer prices, and corporate margins. This guide breaks down the ...